A phase II randomized study of ramucirumab (IMC-1121B) with or without dacarbazine (DTIC) in patients (pts) with metastatic melanoma (MM) Meeting Abstract
| Authors: | Carvajal, R. D.; Wong, M. K.; Thompson, J. A.; Gordon, M. S.; Lewis, K. D.; Pavlick, A. C.; Wolchok, J. D.; Fox, F. E.; Schwartz, J. D.; Badikian, A. Y. |
| Abstract Title: | A phase II randomized study of ramucirumab (IMC-1121B) with or without dacarbazine (DTIC) in patients (pts) with metastatic melanoma (MM) |
| Meeting Title: | 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 28 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2010 Jun 4-8 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2010-05-20 |
| Start Page: | 615s |
| Language: | English |
| ACCESSION: | WOS:000208852005189 |
| DOI: | 10.1200/jco.2010.28.15_suppl.8519 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 8519 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
